ECOR electroCore

electroCore to Participate at Upcoming Investor Conferences

electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be participating at the H.C. Wainwright 24th Global Investment Conference and Ladenburg Thalmann 2022 Healthcare Conference.

H.C. Wainwright 24th Annual Global Investment Conference

Date:  Wednesday, September 14, 2022

Time: 12:30 - 1:00 PM EDT

Event: Fireside Chat

Ladenburg Thalmann 2022 Healthcare Conference

Date: Thursday, September 29, 2022

Time: 3:30 - 3:55 PM EDT

Event: Presentation

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit .

Investors:

Rich Cockrell

CG Capital

404-736-3838



EN
06/09/2022

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces First Quarter 2025 Financial Results

electroCore Announces First Quarter 2025 Financial Results First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to it...

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (...

May 2, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore’s Truvaga™ Now Works with the Apple Health app

electroCore’s Truvaga™ Now Works with the Apple Health app ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Dir...

May 1, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce First Quarter March 31, 2025 Financial Results...

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025 ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 7, 4:30 PM ESTDial-In: (646) 9...

April 30, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effe...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Am...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch